AstraZeneca Pharma India Limited has posted a 33% year-on-year increase in total revenue from operations to Rs. 22,755.8 million for the financial year ended March 31, 2026.

This strong financial performance was driven by sustained growth across its Oncology, Biopharmaceuticals, and Rare Disease portfolios.

The science-led biopharmaceutical company recorded a profit before exceptional items and tax of Rs. 2,574.5 million for FY26, while profit after exceptional items and tax stood at Rs. 1,875.2 million. For the fourth quarter ended March 2026, revenue from operations reached Rs. 5,786.1 million, with profit after tax of Rs. 448.8 million.

Oncology remained the company's largest therapy area, contributing Rs. 16,100.9 million in revenue during FY26. The biopharmaceuticals segment, encompassing Cardiovascular, Renal & Metabolism (CVRM), Respiratory & Immunology (R&I), and Vaccines & Immune Therapies (V&I), generated Rs. 5,243.2 million. The Rare Disease portfolio contributed Rs. 214.6 million.

A key highlight of the year was the receipt of 11 new regulatory approvals for medicines and indications, reinforcing AstraZeneca India's commitment to accelerating access to innovative therapies and addressing unmet medical needs across the country.

Bhavana Agrawal, Chief Financial Officer and Director of AstraZeneca Pharma India, said the company's strong and consistent growth was driven by the resilience of its business, the strength of its science-led portfolio, and disciplined execution across the organization.

"Our performance reflects not only commercial momentum, but also our continued commitment to creating sustainable value through innovation, responsible growth, and meaningful impact for patients, society, and the planet," she said.

Praveen Rao Akkinepally, Country President and Managing Director of AstraZeneca India, said the company's FY26 performance reflects its progress in accelerating the delivery of innovative medicines across key therapy areas.

"With a strong pipeline and a clear sense of purpose, we remain focused on addressing unmet medical needs, advancing the healthcare ecosystem, and creating long-term impact through science-led innovation," he added.